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ABSTRACT: The first cationic heterobimetallic complexes of the type
fac-[Re(CO)3(NHC)(LAuPPh3)]
+, where NHC is an imidazole pyridine-
based carbene and L is 3-pyridylalkyne, 4-pyridylalkyne, or 5-ethynyl-1-
methyl-1H-imidazole, have been synthesized together with their Re(I)
precursors. All of them have showed similar emissive properties resulting
from the presence of the NHC system within the Re(I) core. Thus,
emission can be ascribed to a phosphorescent process with a mixture of a
MLCT from the Re(dπ)→ NHC(π*), LLCT from the imidazolyl/pyridyl
to the NHC ligand, and LC (NHC derivative) transitions. In all cases, the
emission maximum is blue-shifted in comparison with that observed in the
typical diimine-Re(I) systems. Only the heterobimetallic species displayed
antiproliferative activity against tumor lung A549 cells, which was
increased after irradiation at 405 nm up to nearly 5 times for complexes
4 and 5. A necrotic process seems to be the preferred cell death mechanism. Fluorescence microscopy showed that only
heterobimetallic complexes 4 and 5 were suitable for cell visualization. Their biodistribution pattern reveals accumulation within
the cytoplasm close to the nucleus and some nucleus permeation. Overall it can be suggested that, whereas the emissive
properties are dominated by the NHC-Re(I) fragment, the anticancer activity is mainly dependent on the Au(I) counterpart.
■ INTRODUCTION
Cancer is a disease that has been a leading cause of death in the
past decade. For that reason, further research into new
anticancer drugs is essential and one of the latest strategies to
tackle this problem is to build bioactive trackable species.1 The
aim of this strategy is the compilation of information regarding
the biodistribution and inner-interplay of drugs with the
biological targets in order to design and deliver a sophisticated
generation of anticancer metallodrugs. Within this framework
several metallic structures combining well-known anticancer
metal species such as cisplatin,2 auranofin,3 and RAPTA4
analogues with either an organic chromophore or an emissive
metallic species have already been described (see Figure 1A).
However, a step forward would be the incorporation of an
emissive species that is able to add extra antiproliferative value
to the metallodrugs. Luminescent Re(I) complexes of the type
fac-[Re(N^N)(CO)3(X/L)]
+/0, where N^N represents a
diimine derivative and X is a halogen or L an N-donor ligand,
have been proven to be excellent cellular imaging agents for
fluorescence microscopy.5 Their emission is generally assigned
to a 3MLCT (metal to ligand charge transfer) transition, where
the diimine is the main ligand contributor.6 As consequence, L
can be easily functionalized to introduce the bioactive fragment
with no alterations of the emissive properties. In general, these
types of Re(I) complexes do not seem to affect the
antiproliferative properties when they are combined with a
bioactive target (Figure 1B).7 However, it was recently
reported that the coordination of a bidentate N-heterocyclic
carbene instead of the typical diimine ligand gives the Re(I)
complex a remarkable anticancer activity against pancreatic
cancer cells (see Figure 1B).8 This was the first and the only
example in which a Re(I) species containing a bidentate N-
heterocyclic carbene has been tested as an anticancer agent,
and on the basis of the promising result it seems clear that the
substitution of the typical diimine ligand for a bidentate NHC
scaffold has been key to achieve an anticancer rhenium drug.
Alternatively antimicrobial activity was also recently found for
rhenium complexes containing monodentate NHC ligands.9
Therefore, it can be postulated that the combination of an
NHC-Re(I) derivative with a metallodrug would be an
excellent approach to maximize the therapeutic potential of a
trackable metallodrug. Additionally, further substitution of L,
which to the best of our knowledge has been only reported as a
halogen for these types of Re(I) bidentate N-heterocyclic
carbene derivatives10 for a neutral N-donor ligand, will deliver
high-potential mitochondrial bioprobes, as (1) cationic species
present a greater predisposition to permeate those cellular
membranes and (2) the N-donor ligand could be easily used as
a linker to build the theranostic agents. Moreover, new
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grounds for the photophysical properties of these types of
Re(I) complexes would be established. It is expected that their
emissive behavior will differ from that seen for the reported
neutral NHC-Re(I) complexes.11
Thus, herein we describe the first approach toward the use
of luminescent N-heterocyclic carbene based Re(I) species as
cell imaging agents as well as building blocks for trackable
anticancer metallodrugs.
■ RESULTS AND DISCUSSION
Synthetic Approach. In previous studies we have
validated the possibility of visualizing bioactive gold(I)
complexes in cancer cells by a combination of the bioactive
metallic fragment with a luminescent Re(I) species, using
either functionalized alkynes or phosphines as linkers.7 In the
present work the focus is on the development of lumininescent
heterobimetallic Re(I)/Au(I) complexes with an improved
antiproliferative activity toward cancer cells. For that,
substitution of the typical diimine ligand within the Re(I)
scaffold by an analogous N-heterocyclic carbene (NHC)
chelate is proposed. These systems would deliver the first
example of a NHC-Re(I)/Au(I) heterobimetallic complex
used for cellular imaging and as an anticancer agent. Similarly
to previous synthetic procedures the N-methyl-N′-2-pyridyli-
midazolium salt was prepared by nucleophilic substitution of
imidazole with 2-bromopyridine followed by an imidazole
alkylation reaction with methyl iodide.12 The N-methyl-N′-2-
pyridylimidazolium salt reacts with silver oxide, forming the
silver carbene that transmetalates in situ with Re(CO)5Cl, in
acetonitrile, to give A in a moderate yield (Figure 2).13 It is
worth noting that the presence of the chelated NHC within the
fac-{Re(I)CO3} core instead of the symmetric diimine ligand
generates a pair of enantioners. Therefore, further modification
of A leads to subsequent racemic mixtures. Afterward,
abstraction of the chloride ligand by silver triflate in
acetonitrile led to the activated Re(I)-NHC species B, which
can be easily derivatized by further substitution of the labile
acetonitrile ligand for the corresponding alkyne derivatives to
give complexes 1−3. In order to prepare the bimetallic Re(I)/
Au(I) species, the Re(I) precursor was stirred in either DCM
or acetonitrile in the presence of Au(acac)PPh3. The
acetylacetonate complex facilitates the deprotonation of the
alkyne and the subsequent coordination of the gold atom to
the triple bond, thus affording the bimetallic complexes 4−6.
All complexes have been characterized by 1H, 13C{1H},
31P{1H} NMR, FT-IR, and UV−vis spectroscopy as well as
mass spectrometry, corroborating the accomplishment of their
synthesis. Analyses of the CO stretching frequencies of all the
complexes corroborate the expected facial arrangements, as
three stretches at ca. 2020, 1940, and ca. 1890 cm−1 for
complexes 1−3 and two stretches for 4−6 at around 2022 and
1900 cm−1 are observed because of the overlap of A′(2) and
A′′ modes into a single broad band. Similar NHC-rhenium
tricarbonyl derivatives presented analogous values.14 More-
over, the heterobimetallic complexes lack a ν(H−CC) band,
which had been observed for their Re(I) precursors, indicating
the coordination of the gold fragment (see Table 1).
Additionally, in all cases, 1H NMR spectra were well-defined
and showed the typical patterns for the N-methyl-N′-2-
pyridylimidazolium and the corresponding pyridyl or imida-
zolyl carbene derivative coordinated to a fac-Re(CO)3 core.
Specifically, the disappearance of the acidic imidazolium
Figure 1. Examples of (A) the combination of bioactive and emissive
fragments and (B) cytotoxicity displayed by either diimine or NHC-
Re(I) derivatives.
Figure 2. Schematic synthetic procedure and depiction of final
complexes 1−6. Legend: (i) K2CO3, 190 °C, 18 h; (ii) MeI, THF,
room temperature, 24 h; (iii) Ag2O, Re(CO)5Cl, CH3CN; (iv)
AgOTf, CH3CN, reflux 5 h; (v) alkynylpyridine derivative, THF,
reflux; (vi) Au(acac)PPh3, DCM.
Table 1. IR Stretching Bands (cm−1) and 31P{1H} and
13C{1H} NMR (ppm) Chemical Shifts (CD2Cl2) of 1−6
IR ν(CO)
IR ν(H−
CC)
31P{1H}
NMR
13C NMR CC−
H/Au
1 2022s, 1926m,
1895s
3238w 78.0b
2 2019s,
1955m,1908s
3236w 79.5
3 2023s,
1945m,1887s
3229w 69.2
4 2023s, 1900s,br 41.5 98.0
5 2021s, 1897br 41.5 99.2
6 2019s, 1893br 41.8 no
aAbbreviations: w, weak; m, medium; s, strong; br, broad; no, not
observed. bCD3CN.
Organometallics Article
DOI: 10.1021/acs.organomet.8b00601
Organometallics XXXX, XXX, XXX−XXX
B
proton signal in the 10−12 ppm region of the 1H NMR
spectrum was observed. Consequently, a new carbenoic carbon
signal appears between 189 and 197 ppm in the 13C NMR
spectra together with the carbonyl carbons, confirming the
coordination of NHC as a bidentate ligand to the rhenium
core.15 Moreover, as a result of the gold triphenylphosphine
coordination, the heterobimetallic complexes 4−6 revealed in
their 1H NMR spectra a new multiplet resonance in the region
between 7.49 and 7.55 ppm due to the presence of the new
fragment, as well as the disappearance of the terminal alkyne
protons present in their precursors at 3.70, 3.62, and 3.50 ppm,
respectively, in concordance with the IR results. In addition to
that, the downfield shift of the alkynyl carbons seen by 13C
NMR spectroscopy upon the coordination of −AuPPh3 and
the single peak at ca. 41 ppm observed by 31P NMR
spectroscopy are consistent with the values obtained for
similar species.7a Further analytical data provided by mass
spectrometry corroborated the accomplishment of the syn-
thesis.
Crystal Structures. Complexes B, 1, and 3 are chiral
complexes and have been crystallized as racemic mixtures by
slow diffusion of Et2O in CH2Cl2 (1, 3) or CH3CN (B).
Molecular structures together with selected bond distances and
angles are presented in Table 2 and Figure 3. The three
complexes presented a single molecule per asymmetric unit,
and their space groups Pn, P21/n, and P21/c, respectively, are
acentric, but not chiral, or centrosymmetric, and both
enantiomers of each of the species can be observed in the
crystal lattice (see Figure S1). In all cases, the rhenium
coordination sphere could be described as a distorted
octahedron, where the three carbonyls are arranged in a facial
disposition. Thus, the NHC system lies on the equatorial plane
together with two carbonyl ligands, whereas the remaining
carbonyl and the corresponding N-donor ligand are located in
the axial positions of the octahedron. The Re−Ccarbene
distances are 2.125(5), 2.130(4), and 2.135(6) Å for
complexes B, 1, and 3, respectively, which are very close to
those values reported for similar carbene Re species.16
Moreover, Re−CO bond distances trans to the NHC unit
were much longer (ca. 1.970 Å) in comparison with the other
Re−CO distances (ca. 1.915 Å) due to the well-known trans
influence of NHC species. Consequently, we observed a
shortening of the C−O bond length of the corresponding
carbonyl trans to the NHC as a result of the lower π-back-
bonding character from the metal to the carbonyl unit (see
Table 2). These bond length differences are in agreement with
the published crystallographic data of similar NHC-rhenium
complexes.11b It is also worth mentioning that the NHC
chelate provides a similar constriction to the complex in
comparison to their analogous bipy17 or phen18 chelates, with
narrow C−Re−N angles at ca. 74°, comparable to those of the
cited bidentate ligands.
Table 2. Relevant Bond Lengths (Å) and Angles (deg) of Complexes B, 1, and 3
complex B complex 1 complex 3
Re(1)−C(1) 1.911(5) Re(1)−C(1) 1.968(4) Re(1)−C(1) 1.921(4)
Re(1)−C(2) 1.972(6) Re(1)−C(2) 1.911(4) Re(1)−C(2) 1.968(6)
Re(1)−C(3) 1.906(6) Re(1)−C(3) 1.935(4) Re(1)−C(3) 1.906(4)
Re(1)−C(4) 2.125(5) Re(1)−C(9) 2.130(4) Re(1)−C(4) 2.135(6)
Re(1)−N(3) 2.202(4) Re(1)−N(1) 2.212(3) Re(1)−N(3) 2.192(4)
Re(1)−N(4) 2.144(5) Re(1)−N(4) 2.225(3) Re(1)−N(4) 2.188(3)
C(1)−O(1) 1.156(6) C(1)−O(1) 1.144(4) C(1)−O(1) 1.141(5)
C(2)−O(2) 1.140(7) C(2)−O(2) 1.149(5) C(2)−O(2) 1.146(7)
C(3)−O(3) 1.1569(7) C(3)−O(3) 1.149(5) C(3)−O(3) 1.155(6)
N(4)−Re(1)−C(3) 175.7(3) N(4)−Re(1)−C(3) 178.7(1) N(4)−Re(1)−C(3) 174.3(2)
C(4)−Re(1)−N(3) 74.6(2) C(9)−Re(1)−N(1) 74.5(1) C(9)−Re(1)−N(3) 74.9(2)
Figure 3. Pov-ray representations of complexes B, 1, and 3 (the triflate counterions are omitted for clarity). Note that the molecular representations
of the complexes correspond to the same chirality.
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Optical Properties. The photophysical properties of
complexes 1−6 were analyzed by UV−vis absorption and
emission spectroscopy in dimethyl sulfoxide solution at room
temperature. The most significant data are collected in Table 3,
Figure 4, and Figures S2 and S3. All of the complexes showed a
similar absorption pattern, with an intense absorption band at
ca. 290 nm that can be attributed to π→ π* transitions within
the NHC ligand and also within the phenyl groups in the case
of the heterobimetallic complexes. Additionally, all of the
complexes presented a lower energy band with relatively small
molar absorptivity above 300 nm. This band could be
attributed to a mixture of MLCT (Re → NHC) and LLCT
(pyridyl/imidazolyl → NHC) transitions, and thus, it is best
described as a MLLCT transition.13,14 With regard to the
emissive properties, these complexes presented blue-shifted
emission maxima in comparison with those of the typical
[Re(CO)3(N^N)L]
0/+.6 Such a blue shift is a result of the
strongly σ donating NHC ligands, which ensure strong ligand
fields with high-lying d−d excited states. Specifically complexes
1, 2, 4, and 5 exhibit a structured emission at ca. 481 nm,
whereas complexes 3 and 6 presented slightly red shifted broad
emission bands at 488 and 490 nm, respectively (see Figure 4
and Figure S3). The fact that the imidazolyl derivatives 3 and 6
presented red-shifted emission maxima in comparison with
their analogues 1, 2, 4, and 5 species could be associated with
the more highly electron donating character of the imidazole vs
pyridyl derivative present in the axial position of the Re(I)
metal center. In consequence, the HOMO orbitals, which are
primarily located in the Re(I), become slightly destabilized and
a red shift of the emission maximum is seen.15a The emissions
could therefore be attributed to a MLLCT transition, i.e. an
MLCT transition from Re(dπ) → NHC(π*) mixed with an
LLCT transition from the imidazolyl/pyridyl to the NHC
ligand. In addition to that, it is also worth mentioning that the
structured emission profile observed especially for complexes
1, 2, 4 and 5 suggests that the MLLCT could be partially
mixed with a 3LC state.13 Demas and DeGraff already
postulated such behavior in the cases where MLLCT and
LC states were energetically similar.19 The significant LC state
contribution to the emission could also be deduced from the
similarities between the excitation and emission profile of the
imidazolium salt itself with that of the complexes (see Figure
S3). Lifetime values at room temperature range from tens to
hundreds of nanoseconds, which are typical of phosphorescent
nature in this family of complexes.15 Additionally, the presence
of the gold fragment grafted in the axial ligand does not seem
to affect the photophysical behavior of the species, which is in
concordance with other heterobimetallic species reported.7a
Biological Properties. The cytotoxic activity of complexes
1−6 as well as their rhenium precursors A and B was
determined by an MTT assay in the lung A549 tumor cell line
(see Table 4). Only the heterobimetallic complexes presented
a significant antiproliferative character, ca. 11 μM. In contrast,
the monometallic rhenium complexes showed cytotoxicity
values of over 50 μM in all cases, which point toward the gold
fragment as the bioactive entity for complexes 4−6. As similar
NHC rhenium derivatives have been proven to dissociate CO
under photochemical conditions,15b complexes A, B, and 1−3
were tested as photocytotoxic agents using the same cell line.
However, irradiation at 405 nm for 10 min did not showed the
expected increase in toxicity. Once again, all of them presented
IC50 values of over 50 μM. In addition to the monometallic
species, the heterobimetallic complexes were also analyzed
under photochemical conditions. All of them showed a slight
improvement in their antiproliferative character (see Table 4),
complex 6 being the least affected by application of the
irradiation. Despite the promising result, these complexes
could not be considered as effective photocytotoxic agents, as
their level of toxicity in the absence of light is already high (ca.
11 μM). The cell death mechanism of heterobimetallic
complexes was investigated by flow cytometry (see Figure
S4). Complex 4 was incubated at different concentrations with
A549 cells for 24 h. Annexin V-DY634 and 7-AAD were used
as fluorescent markers. Annexin V-DY634 binds to phospha-
tidylserine in the cell membrane, and 7-AAD is a vital dye that
only enters through a damaged cell membrane. Moreover, Z-
VAD-fmk, a cell permeant pan caspase inhibitor, was used as
an indicator of the participation of caspases in cell death. Since
Table 3. Photophysical Properties of 1−6 in Degassed
DMSO Solutiona
λabs/nm (ε/L mol
−1 cm−1) λem/nm (λem/nm) τ/ns
1 288 (14000), 320 (8000) 440, 460 (s) (400)
2 291 (14800), 317 (10900) 456, 481 (s), 514 (413) 212
3 286 (10100), 323 (5800) 488 (370) 10, 136
4 285 (36700), 316 (14600) 460, 485 (s), 514 (414) 31, 205
5 288 (30300), 310 (28170) 465, 483 (s), 512 (412) 207
6 280 (25400), 339 (4000) 493 (377) 15, 123
aAerated DMSO: τ(2) = 175 ns. Degassed DMSO: imidazolium salt:
λem 440 nm (λexc 295 nm); A: λem 506 nm (λexc 401 nm).
Abbreviation: s, strong.
Figure 4. Emission spectra of complexes 5 and 6 in degassed DMSO
at 298 K.
Table 4. IC50 Values of 1−6 in A549 Cells after Incubation
for 24 h in the Absence of Light and after Irradiation for 10
min at 405 nm
IC50 IC50 (irradiated)
1 >50 >50
2 >50 >50
3 >50 >50
4 12.18 ± 1.19 4.48 ± 0.71
5 10.82 ± 1.63 2.66 ± 0.56
6 12.65 ± 2.10 9.97 ± 3.04
A >50 >50
NHC >50 >50
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the cells incubated with both markers seemed to have a
positive response by flow cytometry together with the speed of
cell death observed, it can be concluded that the cell death
mechanism is likely to be by a necrotic process. Moreover, the
fact that the cells incubated with Z-VAD-fmk behave in the
same way that those lacking such a caspase inhibitor
corroborates that the cellular death is following a pathway
independent of caspases (see Figure S5). Additionally, a similar
experiment was performed but this time with irradiation of the
samples for 10 min at 405 nm during the incubation period in
order to assess whether the irradiation process was somehow
affecting the cellular death pathway. Once again the result was
similar to that of the nonirradiated experiment; necrosis seems
to be the preferred cellular death. Investigations regarding the
biological targets for these complexes were also undertaken.
Thus, inhibition of the thioredoxin reductase was performed
using complex 4 as a model. Specifically, A549 cells were
treated with complex 4 or vehicle (DMSO) for 4 h. Then, total
protein extracts were prepared and used for the determination
of thioredoxin activity. Thereafter, the artificial substrate 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB) was added, which
would rapidly evolve to two molecules of 2-nitro-5-
thiobenzoate anion (TNB) if thioredoxin reductase is in the
presence of NADPH. The reduction of DTNB to TNB affords
a yellow color that can be detected at 412 nm by UV−vis
absorption.20 The evolution of the TNB formation was
recorded for 5 min, and its comparison with that of a control
assay did not show inhibition of the thioredoxin (see Figure 5).
This result was further confirmed by a preliminary analysis of
the production of reactive oxygen species (ROS) in colorectal
adenocarcinoma cells (CACO cells). Once again, incubation of
complex 4 with CACO cells did not promote the production of
ROS, which suggests a biological target different from that of
thioredoxin.
In an attempt to elucidate the biodistribution of complexes
1−6, fluorescence microscopy was used. The species were
incubated with A549 cells for 24 h at a concentration lower
than their IC50 value in order to prevent cell death during the
experiment. In addition, Draq5, a nuclear dye with an
excitation wavelength of 647 nm, was used as an internal
standard to ascertain their localization. Cellular images were
taken after exciting the cells at 405 nm, where the emissive
complexes could be visualized. Superimposition of those
images with the corresponding images taken after exciting
the samples at 647 nm allowed elucidation of whether the
complexes 1−6 were within the cell and/or inside the nucleus.
Unexpectedly, none of the monometallic rhenium complexes
were visible within this assay. In contrast, two out of the three
heterobimetallic complexes showed emission within the
cytoplasm surrounding the nucleus and in a smaller amount
inside the nucleus (Figures 6 and 7). Specifically, 4 and 5 were
the complexes that were able to be visualized within the cell. A
closer look at other heterobimetallic Re(I)/Au(I) complexes
reported in the literature as possible cell visualization or
theranostic agents indicates that typically those containing in
their structure the fragment AuPPh3 appear to have more
permeability in comparison to their monometallic rhenium
analogues.7 The present case seems to follow the same trend
except for complex 6, which despite having a −AuPPh3
fragment was not observable. A plausible explanation for this
result might relay on the photophysical properties of complex
6. In contrast to complexes 4 and 5, whose maximum
excitation wavelengths were at around 410 nm in both cases, in
complex 6 the maximum excitation was at 377 nm (see Table 3
and Figure S3). Therefore, irradiation of the cells at 405 nm
would not be suitable to excite complex 6, and consequently
emission would not be observed. This result is in line with the
lower photocytotoxicity seen in the case of complex 6 in
Figure 5. Inhibition of thioredoxin assay for complex 4:
representation of the evolution of absorbance intensity of TNB over
5 min.
Figure 6. Images of complexes 4 (top row) and 5 (bottom row)
incubated with A459 cells and Draq5 at 37 C for 4 h: (A) after
irradiation at 405 nm; (B) after irradiation at 647 nm; (C)
superimposed image.
Figure 7. Image of complex 5 (yellow color) incubated with A459
cells and Draq5 (blue color) at 37 C for 4 h superimposed with the
bright field image.
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comparison with complexes 4 and 5 (see Table 4). It is
possible that the irradiation used is not equally effective.
As previously commented, complexes 1−3 were not suitable
for cell imaging within these conditions. To assess whether a
possible disruption of the molecules under biological
conditions was taking place, thus preventing their visualization,
a stability assay was performed. Specifically, complexes 1 and 4
were chosen as representative species and they were dissolved
in a mixture of DMSO and PBS (<0.5% DMSO). The stability
of the complexes was analyzed by UV−vis absorption
spectroscopy over a period of 24 h. Both complexes seemed
to remain stable under those conditions (see Figure S6).
Therefore, it seems clear that decomposition of the complexes
could not be the origin of the lack of response in the
localization experiment for the monometallic species 1−3. The
main difference between these Re(I) species and those already
studied by fluorescence microscopy is the nature of the
chelated ligand.21 Thus, changing the typical diimine ligand for
a pyridyl-carbene derivative (NHC) seems to negatively affect
the internalization process.
■ CONCLUSIONS
In summary, the first bioactive and luminescent heterobime-
tallic Re(I)/Au(I) complexes containing a pyridyl N-
heterocyclic carbene derivative instead of the typical diimine
ligand were reported, as well as their monometallic Re(I)
precursors. Either pyridyl or imidazolyl alkyne derivatives were
used as bridging ligands between both metals, being specifically
bonded to the Re(I) center through the nitrogen atom and to
the Au(I) center through the alkynyl carbon. The photo-
physical properties of these complexes showed that all of them
have a similar behavior, where the presence of the Au(I)
fragment was not implicated in the emissive process. Thus, the
emission was attributed to a mixture of 3MLCT from Re(dπ)
→ NHC(π*) and 3LLCT from the imidazolyl/pyridyl to the
NHC ligand as well as 3LC (NHC derivative) transitions. The
similar structured emission profiles seen for NHC, 1, 2, 4, and
5 was conclusive on the implication of LC transitions.
Moreover, such an LC contribution seems to be less marked
in the case of complexes with axial ligands such as a chloride
(A) or imidazolyl derivatives (3 and 6), whose electron-
donating character is higher, and presumably the contribution
of the LLCT over the LC transition as well. As expected, only
the heterobimetallic complexes showed antiproliferative
character against A549 cells (IC50 ≈ 11 μM). Therefore, at
this point it can be stated that we have developed
heterobimetallic species able to combine their intrinsic
emissive (Re(I) fragment) and bioactive (Au(I) fragment)
properties into a single new molecular structure. Additionally,
irradiation of the cells incubated with the heterobimetallic
complexes at 405 nm incremented the cytotoxicity up to 5
times in some cases. In contrast, monometallic Re(I) species
did not show any extra antiproliferative activity. The cell death
mechanism studied by flow cytometry concluded that a
necrotic process seems to take place for the irradiated and
nonirradiated assays. Moreover, fluorescence microscopy
analysis showed that only 4 and 5 were able to accumulate
within the cells. Specifically, their emission was within the
cytoplasm surrounding the nucleus and in a smaller amount
inside the nucleus. The fact that none of the monometallic Re
complexes were detected by this technique could be a
combination of several factors. Photophysical (lower intensity
or quenching processes in the biological media) and/or the
different lipophilic properties (lack of the gold triphenyl
fragment and the presence of a pyridyl-NHC derivative instead
of the typical diimine) could be implicated. Additionally, the
different photophysical properties seem to be the origin for the
inability to detect 6 by fluorescence microscopy. In this
particular case we believe that it is possible that the complexes
have entered the cells, as it is known that the fragment AuPPh3
renders a higher lipophilicity of the probe and, thus, a better
cell permeability. However, this complex has a maximum
excitation wavelength of ca. 370 nm, which is quite far from the
excitation wavelength used within the visualization experiment
(405 nm).
To conclude, the development of heterobimetallic Re(I)/
Au(I) complexes as emissive and bioactive species could be
achieved on attending to the different functionalizations of (a)
the chelate ligand NHC to modulate the desired photophysical
properties and (b) the bridging and ancillary gold ligands in
order to endow specific bioactivity.
■ EXPERIMENTAL SECTION
General Measurements and Analysis Instrumentation. Mass
spectra were recorded on a Bruker Esquire 3000 Plus instrument, with
the electrospray (ESI) technique, and on a Bruker MALDI-TOF
instrument. 1H, 13C{1H}, and 31P{1H} NMR, including 2D experi-
ments, were recorded at room temperature on a Bruker Avance 400
spectrometer (1H, 400 MHz; 13C, 100.6 MHz; 31P, 162 MHz) with
chemical shifts (δ, ppm) reported relative to the solvent peaks of the
deuterated solvent. Infrared spectra were recorded in the range 4000−
250 cm−1 on a PerkinElmer Spectrum 100 FTIR spectrometer. Room-
temperature steady-state emission and excitation spectra were
recorded with a Jobin-Yvon-Horiba Fluorolog FL3-11 spectrometer
fitted with a JY TBX picosecond detection module. Nanosecond
lifetimes were recorded with a Datastation HUB-B apparatus with a
nanoLED controller and DAS6 software. The nanoLEDs employed
for lifetime measurements had wavelengths of 370 and 390 nm. The
lifetime data were fitted using the Jobin-Yvon software package and
the Origin Pro 8 program. UV−vis spectra were recorded with 1 cm
quartz cells on an Evolution 600 spectrophotometer. The quantum
yields were measured in a Hamamatsu Photonics Quantaurus-QY
instrument at 300−950 nm.
Crystal Structure Determinations. Crystals were mounted in
inert oil on glass fibers and transferred to the cold gas stream of an
Oxford Diffraction Xcalibur diffractometer equipped with a low-
temperature attachment. Data were collected using monochromated
Mo Kα radiation (λ= 0.71073 Å), with scan type ω. Absorption
corrections based on multiple scans were applied using spherical
harmonics implemented in the SCALE3 ABSPACK scaling algorithm.
The structures were solved by direct methods and refined on F2 using
the program SHELXL-97.22All non-hydrogen atoms were refined
anisotropically, with the exception of complex 7. CCDC deposition
numbers 1858777 (B), 1858778 (1), and 1858779 (3) contain the
supplementary crystallographic data. These data can be obtained free
of charge from the Cambridge Crystallography Data Center.
Antiproliferative Studies: MTT Assay. Exponentially growing
cells (A549) were seeded at a density of approximately 104 cells per
well in 96-well flat-bottomed microplates and allowed to attach for 24
h prior to addition of the compounds. The complexes were dissolved
in DMSO and added to cells in concentrations ranging from 10 to 200
μM in quadruplicate. Cells were incubated with our compounds for
24 h at 37 °C. A 10 μL portion of MTT (5 mg mL−1) was added to
each well, and the plates were incubated for 2 h at 37 °C. Finally, the
growth medium was eliminated and DMSO (100 μL per well) was
added to dissolve the formazan precipitates. The optical density was
measured at 550 nm using a 96-well multiscanner autoreader
(ELISA). The IC50 values were calculated by nonlinear regression
analysis.
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Flow Cytometry Assay. The cells were treated for 24 h with
compound 4 at 5, 10, and 25 μM. Then, they were trypsinized and
incubated at 37 °C for 5 min in ABB (140 mM NaCl, 2.5 mM CaCl2,
10 mM Hepes/NaOH, pH 7.4) containing 0.5 mg mL−1 of either
annexin V-DY634 or 7-AAD. Finally, the cells were diluted to 0.5 mL
with ABB and analyzed by flow cytometry (FACScan, BD
Biosciences, Spain).
Thioredoxin Inhibition Assay. For determination of the
thioredoxin reductase activity, A549 cells were incubated for 9 h
with our compounds at different concentrations near the IC50 values.
Cells were collected, washed with PBS and 150 μL of buffer (1%
Triton X-100, 150 mM NaCl, 50 mM Tris/HCl pH 7.6, 10% v/v
glycerol, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, 10 μg mL−1 leupeptin, 10 mM NaF, 1 mM sodium
methylsulfonium) for 30 min at 0 °C, and centrifuged at 200g for 10
min at 4 °C. The protein was quantified using the BCA protein assay
(Thermo Scientific), and 80 μg was added in each assay. Kinetic
studies were performed in a buffer containing 0.2 M NaCl, H-
phosphate pH 7.4, 2 mM EDTA, 0.25 mM NADPH, and 3 mM
DTNB. The increase in the absorbance was measured at 412 nm for 5
min at 25 °C.
Intracellular Peroxide (ROS) Formation. The production of
ROS (reactive oxygen species) was assessed using the dichloro-
fluorescein (DCF) assay.23 Caco-2/TC7 cells were plated in 96-well
plates at a density of 4000 cells per well and incubated for 24 h under
standard cell culture conditions. For treatment, 4 was added to cells
within its IC50 concentration and incubated for 24 h; mock treated
cells were just incubated with DMSO at the same concentration as for
treated cells. Then, cells were washed twice with PBS and 100 μL of
20 mM DCFH-DA (dichlorodihydrofluorescein diacetate) was added
to each well. Cells were incubated for 1 h at 37 °C and washed twice
with PBS; finally, 100 μL of PBS was added and the fluorescence was
analyzed with DTX-880 (Beckman Counter). Excitation and emission
settings were 485 and 535 nm, respectively. The intensity of
fluorescence is considered a reflection of total intracellular ROS.
Cell Fluorescence Microscopy Study. Cells from the European
Collection of Cell Cultures were maintained in Hepes-modified
minimum essential medium (DMEM) supplemented with 5% fetal
bovine serum, penicillin, and streptomycin. A549 cells were detached
from the plastic flask using trypsin-EDTA solution and suspended in
an excess volume of growth medium. The homogeneous cell
suspension was then distributed into 24-well flat-bottomed micro-
plates over a cover slip placed inside each well, and they were allowed
to attach for 24 h prior to addition of compounds. Complexes were
added (10 μL) to the cells up to a final concentration of 25 μM. After
incubation for 4 h at 37 °C, the growth medium was removed and 0.5
mL of PBS was added for a washing step (three times). Thereafter, 0.5
mL of paraformaldehyde (4%) was added and the plates were allowed
to stand for 15 min at room temperature. Eventually the
paraformaldehyde was removed and further washings with PBS
were performed (3 × 0.5 mL). The cover slips were collected from
the 24-well plate, immersed for 1 or 2 s in distilled water, and left in
order to allow the water to drip off. Then, they were placed over a
microscope slide where a drop of Fluoromount with 2 μM DRAQ5
had been previously placed. Preparations were viewed using an
Olympus FV10-i Oil type compact confocal laser microscope using a
×10 or ×60 objective, with excitation wavelengths at 405 and 650 nm.
Materials and Procedures. The starting materials N-methyl-N′-
2-pyridylimidazolium,12 Au(acac)(PPh3),
24 and complex A13 were
prepared according to literature procedures, and their experimental
data agree with those reported elsewhere. All other starting materials
and solvents were purchased from commercial suppliers and used as
received unless otherwise stated.
Synthesis of Complex B. To a stirred solution of A (83 mg,
0.178 mmol) in CH3CN (20 mL) was added AgOTf (50.4 mg, 0.196
mmol), and the mixture was refluxed over 5 h 30 min in the dark. The
suspension was filtered over Celite and the solvent reduced to
minimum volume. The addition of cold ether afforded an oil that after
trituration gave the product as a pale yellow solid (yield 83 mg, 79%).
1H NMR (400 MHz, CD2Cl2): δ 8.76 (ddd, J = 5.6, 1.6, 0.7 Hz, 1H,
H6), 8.25 (ddd, J = 8.4, 7.6, 1.6 Hz, 1H, H4), 8.14 (d, J = 2.2 Hz, 1H,
H8 or H9), 8.13−8.10 (ddd, J = 8.4, 1.2, 0.7 Hz, 1H, H3), 7.44 (ddd, J
= 7.5, 5.6, 1.2 Hz, 1H, H5), 7.29 (d, J = 2.2 Hz, 1H, H8 or H9).
13C
NMR (101 MHz, CD2Cl2): δ 195.0 (s, CO), 194.7 (s, CO), 189.2 (s,
CO), 187.0 (s, C7), 154.3 (s, C2), 153.8 (s, C6), 143.7 (s, C4), 125.8
(s, C8 or C9), 124.8 (s, C5), 118.90 (s, C8 or C9), 114.32 (s, C3),
39.78 (s, C10), 4.32 (s, C12). HRMS (m/z): 471.0470 [M − OTf],
calcd for C14H12N4O3Re 471.0462. IR (ν, cm
−1): 3155 (CAr−H),
2027, 1882 (CO), 1621 (CAr=N)
General Procedure for Coordination Synthesis of 1−3. To a
stirred solution of B in THF was added the corresponding
alkynylpyridine ligand, and the reaction mixture was heated for
several hours until consumption of the starting material. The solvent
was then evaporated and the crude mixture redissolved in DCM.
Filtration over Celite followed by addition of ether afforded the
desired product as a pale yellow solid.
Synthesis of Complex 1. Complex B (30 mg, 0.048 mmol) and 3-
ethynylpyridine (25 mg, 0.242 mmol) were reacted in THF (5 mL) at
40 °C over 32 h (yield 23.7 mg, 72%). 1H NMR (400 MHz,
CD3CN): δ 8.99 (d, J = 5.6 Hz, 1H, H6), 8.39 (d, J = 1.7 Hz, 1H,
H15), 8.26−8.20 (m, 2H, H4 + H11), 7.93−7.89 (dtap, J = 8.0, 1.6 Hz,
1H, H13), 7.89 (d, J = 2.2 Hz, 1H, H9/H8), 7.85 (dm, J = 8.4 Hz, 1H,
H3), 7.52 (ddd, J = 7.5, 5.6, 1.1 Hz, 1H, H5), 7.39 (d, J = 2.2 Hz, 1H,
H9/H8), 7.29 (ddd, J = 8.0, 5.7, 0.6 Hz, 1H, H12), 4.10 (s, 3H, H10),
3.70 (s, 1H, H17).
13C NMR (101 MHz, CD3CN): δ 197.6 (s, CO),
191.3 (s, CO), 190.3 (s, C7), 157.1 (s, C15), 154.8 (s, C11), 154.7 (s,
C6), 154.6 (s, C2), 144.1 (s, C4), 143.0 (s, C13), 127.3 (s, C12), 126.7
(s, C9), 125.8 (s, C5), 123.0 (s, C14), 119.0 (s, C8), 114.5 (s, C13),
84.8 (s, C17, (CC-H)), 78.0 (s, C16, (CC−H)), 39.9 (s, C10). HRMS
(m/z): 533.0620 [M − OTf], calcd for C19H14AuN4O3Re 533.0618.
IR (ν, cm−1): 3238 (CC−H), 3238 (CAr−H), 2113 (CC), 2022,
1926, 1895 (CO), 1618 (CArN).
Synthesis of Complex 2. 4-Ethynylpyridine hydrochloride (85 mg,
0.609 mmol) was dissolved in a saturated aqueous solution of
NaHCO3 and extracted with DCM. The organic phase was dried with
anhydrous sodium sulfate and the solvent evaporated to dryness to
afford 4-ethynylpyridine. Then the alkynylpyridine was reacted with
complex B following the same procedure described for complex 1 (30
mg, 0.0484 mmol) in THF (5 mL) (yield 29.2 mg, 88%). 1H NMR
(400 MHz, CD2Cl2): δ 8.88 (ddd, J = 5.6, 1.6, 0.7 Hz, 1H, H6), 8.26
(ddd, J = 8.4, 7.5, 1.7 Hz, 1H, H4), 8.21 (dd, J = 5.1, 1.5 Hz, 2H, H11),
8.19 (d, J = 2.2 Hz, 1H, H9), 8.16 (ddd, J = 8.4, 1.7, 1.2 Hz 1H, H3),
7.50 (ddd, J = 7.5, 5.6, 1.2 Hz, 1H, H5), 7.35 (d, J = 2.2 Hz, 1H, H8),
7.33 (dd, J = 5.1, 1.5 Hz, 2H, H12), 4.12 (s, 3H, H10), 3.62 (s, 1H,
H15).
13C NMR (101 MHz, CD2Cl2): δ 197.4 (s, CO), 197.0 (s, CO),
190.3 (s, CO or C7), 190.3 (s, CO or C7), 154.1 (s, C12), 154.1 (s,
C2), 153.8 (s, C6), 144.1 (s, C4), 134.2 (s, C13), 129.7 (s, C12), 126.3
(s, C9), 125.6 (s, C3), 119.1 (s, C8), 114.7 (s, C5), 87.6 (s, C15, (CC-
H)), 79.5 (s, C14, (CC−H)), 39.8 (s, C10). HRMS (m/z): 533.0644
[M − OTf], calcd for C19H14AuN4O3Re 533.0618. IR (ν, cm−1):
3236 (CC−H), 3236 (CAr−H), 2117 (CC), 2019, 1955, 1908
(CO), 1620 (CArN).
Synthesis of Complex 3. Complex B (56.6 mg, 0.091 mmol) and
5-ethynyl-1-methyl-1H-imidazole (9.6 μL, 0.091 mmol) were reacted
in THF (5 mL) at 40 °C for 24 h. Purification was carried out by
recrystallization in acetone/ether (yield 23.1 mg, 70%). 1H NMR
(400 MHz, CD2Cl2): δ 8.81 (ddd, J = 5.6, 1.6, 0.6 Hz, 1H, H6), 8.20
(ddd, J = 8.4, 7.6, 1.6 Hz, 1H, H4), 8.07 (d, J = 2.2 Hz, 1H, H8), 8.03
(ddd, J = 8.4, 1.1, 0.6 Hz, 1H, H3), 7.42 (ddd, J = 7.5, 5.6, 1.1 Hz, 1H,
H5), 7.32 (d, J = 2.2 Hz, 1H, H9), 7.30 (sap, 1H, H16), 6.96 (d, J = 1.3
Hz, 1H, H11), 4.06 (s, 4H, H10), 3.59 (s, 3H, H15), 3.56 (s, 1H, H14).
13C NMR (101 MHz, CD2Cl2): δ 197.4 (s, CO), 197.1 (s, CO),
190.8 (s, CO or C7), 189.7 (s, CO or C7), 153.9 (s, C2), 153.5 (s, C6),
143.4 (s, C4), 142.6 (s, C16), 136.8 (s, C11), 126.0 (s, C9), 125.1 (s,
C5), 118.7 (s, C8), 118.2 (s, C12), 114.4 (s, C3), 87.2 (s, C14, (CC-
H)), 69.2 (s, C13, (CC−H)), 39.9 (s, C10), 33.6 (s, C15). HRMS (m/
z): 536.0738 [M − OTf], calcd for C18H15N5O3Re 536.0727. IR (ν,
cm−1): 3229 (CC−H), 3129 (CAr−H), 2125 (CC), 2023, 1945,
1887 (CO), υ 1617 (CArN).
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General Procedure for Gold Addition. To a stirred solution of
the rhenium precursor (1, 2 , or 3) in acetonitrile or dichloromethane
(5 mL) was added Au(acac)PPh3. After 5 h of stirring at room
temperature in the dark, the solution was filtered over Celite and
concentrated to dryness. The solid was redissolved in DCM, and
addition of ether afforded the desired product as a solid.
Synthesis of Complex 4. Complex 4 was obtained by following the
general procedure for gold addition. Specifically, compound 1 (58 mg,
0.085 mmol) and Au(acac)PPh3 (47.5 mg, 0.085 mmol) were stirred
in DCM (5 mL), affording the desired product as an orange solid
(yield 32.6 mg, 34%). 1H NMR (400 MHz, CD2Cl2): δ 8.89 (dd, J =
5.6, 1.6 Hz, 1H, H6), 8.37−8.36 (m, 1H, H14), 8.26 (ddd, J = 8.5, 7.6,
1.6 Hz, 1H, H4), 8.21 (d, J = 2.2 Hz, 1H, H8), 8.17 (dbr, J = 8.4 Hz,
1H, H3), 7.87 (dd, J = 5.6, 1.4 Hz, 1H, H11), 7.76 (dd, J = 8.0, 1.4 Hz,
1H, H13), 7.60−7.46 (m, 20H, HAr+H5), 7.34 (d, J = 2.2 Hz, 1H, H9),
7.16 (ddd, J = 8.0, 5.7, 0.6 Hz, 1H, H12), 4.13 (s, 3H, H10).
13C NMR
(101 MHz, CD2Cl2): δ 197.6 (s, CO), 197.1 (s, CO), 190.6 (s, C7),
190.2 (s, CO), 157.0 (s, C14), 154.1 (s, C2), 153.4 (s, C6), 150.6 (s,
C11), 144.1 (s, C4), 142.3 (s, C13), 134.8 (d,
2JP−C = 13.8 Hz, 6C, o-C,
Ph), 132.4 (d, 4JP−C = 2.2 Hz, 3C, p-C, Ph), 129.9 (d,
1JP−C = 56.3 Hz,
3C, i-C, Ph), 129.9 (d, 2JP−C = 11.4 Hz, 6C, m-C, Ph), 126.7 (s, C12),
126.5 (s, C15), 126.2 (s, C9), 125.51 (s, C5), 119.2 (s, C8), 98.0 (brs,
C16, (CC−H)), 114.7 (s, C3), 39.8 (s, C10). C17 (CC-Au) no
observed. 31P NMR (162 MHz, CD3CN): δ 41.49. HRMS (m/z):
991.1122 [M − OTf], calcd for C37H28AuN4O3PRe 991.1118. IR (ν,
cm−1): 3124 (CAr−H), 2125 (CC), 2023, 1900 (CO), 1617
(CArN).
Synthesis of Complex 5. Complex 5 was obtained by following the
general procedure for gold addition. Specifically, compound 2 (30 mg,
0.044 mmol) and Au(acac)PPh3 (24.6 mg, 0.044 mmol) were stirred
in acetonitrile (5 mL), affording the desired product as a red solid
(yield 31.2 mg, 62%). 1H NMR (400 MHz, CD2Cl2): δ 8.89 (dd, J =
5.6, 0.9 Hz, 1H, H6), 8.37−8.35 (m, 1H, H14), 8.29−8.23 (m, 1H,
H4), 8.21 (d, J = 2.2 Hz, 1H, H8), 8.17 (dm, J = 8.3 Hz, 1H, H3),
7.88−7.85 (dm, J = 5.7 Hz, 1H, H11), 7.76 (dm, J = 8.0 Hz, 1H, H13),
7.61−7.46 (m, 15H, HAr), 7.34 (d, J = 2.2 Hz, 1H, H9), 7.17 (ddd, J =
8.0, 5.7, 0.7 Hz, 1H, H12), 4.13 (s, 3H, H10).
13C NMR (101 MHz,
CD2Cl2): δ 197.7 (s, CO), 197.2 (s, CO), 190.6 (s, C7), 190.5 (s,
CO), 154.1 (s, C6), 153.3 (s, 3C, C11+C2), 144.0 (s, C4), 137.5 (s,
C13), 134.7 (d,
2JP−C = 13.8 Hz, 6C, o-C, Ph), 132.35 (d,
4JP−C = 2.4
Hz, 3C, p-C, Ph), 129.8 (d, 3JP−C = 11.4 Hz, 6C, m-C, Ph), 129.7 (d,
1JP−C = 56.9 Hz, 3C, i-C, Ph), 129.7 (s, 2C, C12), 126.2 (s, C9), 125.4
(s, C3), 119.2 (s, C8), 114.6 (s, C5), 99.2 (br s, C14, (CC−Au)), 39.8
(s, C10). C15(CC-Au) not observed.
31P NMR (162 MHz, CD3CN): δ
41.49. HRMS (m/z): 991.1121 [M − OTf], calcd for
C37H28AuN4O3PRe 991.1118. IR (ν, cm
−1): 3124 (CAr−H), υ 2117
(CC), 2021, 1897 (CO), υ 1602 (CArN).
Synthesis of Complex 6. Complex 6 was obtained following the
general procedure for the gold addition. Specifically, compound 3 (1
equiv, 17.8 mg, 0.026 mmol) and Au(acac)PPh3 (1 equiv, 14.6 mg,
0.026 mmol) were stirred in acetonitrile (5 mL), affording the desired
product as a beige solid (yield 16.8 mg, 52%). 1H NMR (300 MHz,
CD2Cl2): δ 8.81 (ddd, J = 5.6, 1.6, 0.7 Hz, 1H, H6), 8.20 (ddd, J = 8.4,
7.6, 1.7 Hz, 1H, H4), 8.09 (d, J = 2.2 Hz, 1H, H8), 8.04 (ddd, J = 8.4,
1.2, 0.7 Hz, 1H, H3), 7.60−7.45 (m, 16H, HAr), 7.41 (ddd, J = 7.5,
5.6, 1.2 Hz, 1H, H5), 7.31 (d, J = 2.2 Hz, 1H, H9), 7.15 (d, J = 1.4 Hz,
1H, H11), 6.59 (d, J = 1.4 Hz, 1H, H12), 4.06 (s, 3H, H10), 3.57 (s,
3H, H14).
13C NMR (75 MHz, CD2Cl2): δ 197.5 (s, CO), 190.1 (s,
CO or C7), 153.8 (s, C2), 153.5 (s, C6), 143.4 (s, C4), 140.6 (s, C11),
134.74 (d, 2J = 14.4 Hz, 6C, o-C, Ph), 133.93 (s, C12), 132.35 (s, p-C,
Ph), 129.86 (d, 1JP−C = 57.3 Hz, 3C, i-C, Ph), 129.73 (d,
3JP−C = 12.0
Hz, 6C, m-C, Ph), 125.94 (s, C9), 125.00 (s, C5), 120.97 (s, C13),
118.64 (s, C8), 114.16 (s, C3), 39.81 (s, C2), 33.25 (s, C2). HRMS
(m/z): 994.1238 [M − OTf], calcd for C36H29AuN5O3PRe 994.1227.
IR (ν, cm−1): 3127 (CAr−H), 2019, 1893 (CO), 1617 (CArN).
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